enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - immunosuppressantit - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
sapropterin dipharma
dipharma arzneimittel gmbh - sapropteriinidihydrokloridi - phenylketonurias - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.
azathioprin medac 25 mg tabletti, kalvopäällysteinen
medac gesellschaft für klinische spezialpräparate mbh - azathioprinum - tabletti, kalvopäällysteinen - 25 mg - atsatiopriini
azathioprin medac 50 mg tabletti, kalvopäällysteinen
medac gesellschaft für klinische spezialpräparate mbh - azathioprinum - tabletti, kalvopäällysteinen - 50 mg - atsatiopriini
levetiracetam hetero europe 250 mg tabletti, kalvopäällysteinen
hetero europe s.l. - levetiracetamum - tabletti, kalvopäällysteinen - 250 mg - levetirasetaami
levetiracetam hetero europe 500 mg tabletti, kalvopäällysteinen
hetero europe s.l. - levetiracetamum - tabletti, kalvopäällysteinen - 500 mg - levetirasetaami
levetiracetam hetero europe 1000 mg tabletti, kalvopäällysteinen
hetero europe s.l. - levetiracetamum - tabletti, kalvopäällysteinen - 1000 mg - levetirasetaami
cinacalcet aristo 30 mg tabletti, kalvopäällysteinen
aristo pharma gmbh - cinacalcetum hydrochloridum - tabletti, kalvopäällysteinen - 30 mg - sinakalseetti